•
KN
KNSA
Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares
yahooPHARMACEUTICAL PREPARATIONS
--
Price Chart
Market Cap
3.17B
Volume
555.20K
52W High
$44.42
52W Low
$18.12
Open
$0.00
Prev Close
$41.03
Day Range
0.00 - 0.00
About Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.
Latest News
Kiniksa Pharmaceuticals Announces U.S. Orphan Drug Designation for KPL-387 for the Treatment of Pericarditis
GlobeNewswire Inc.•Oct 17
Kiniksa Pharmaceuticals Announces Trial Design of Planned Phase 2/3 Clinical Trial of KPL-387 in Recurrent Pericarditis
GlobeNewswire Inc.•Jun 5
Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences
GlobeNewswire Inc.•May 29
3 No-Brainer Healthcare Stocks to Buy With $1,000 Right Now
The Motley Fool•Mar 14
Kiniksa Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025
GlobeNewswire Inc.•Feb 20
Evolving Landscape of Cardiology Segment: Key Market Insights of Latest Published Rare Cardiovascular Diseases Report — Giant-Cell Arteritis, Pulmonary Arterial Hypertension, and Restrictive Cardiomyopathy | DelveInsight
GlobeNewswire Inc.•Jan 14
Urticaria Clinical Trial Pipeline Accelerates: 20+ Leading Companies Pioneering New Treatments | DelveInsight
GlobeNewswire Inc.•Nov 4
Kiniksa Pharmaceuticals Sponsors American Heart Association’s Addressing Recurrent Pericarditis Initiative
GlobeNewswire Inc.•Jun 17